Vitiligo -- KOL Insight

While KOLs say Incyte Corporation's Opzelura is a significant advance over existing treatments for vitiligo, what factors do they identify that could initially limit uptake? Why are dermatologists sceptical about the prospects for Pfizer's pipeline JAK inhibitor ritlecitinib in vitiligo? What advantages do KOLs see for IL-15 inhibitors such as Amgen's ordesekimab? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary

Treatment algorithm for vitiligo

Research objectives

Janus kinase (JAK) inhibitors

• Marketed therapies
  • Opzelura (ruxolitinib; Incyte Corporation)
• Pipeline therapies
  • Ritlecitinib (PF 6651600; Pfizer)
  • Rinvoq (upadacitinib; AbbVie)
  • Povorcitinib (INCB054707; Incyte Corporation)

PDE4 Inhibitors

• Pipeline therapies
  • Crisaborole (AN-2728) and PF 07038124 (Pfizer)

Monoclonal antibodies

• Pipeline therapies
  • Ordesekimab (AMG 714; Amgen)
  • EB06 (NI-0801; Edesa Biotech/Light Chain Biosciences)

MC1R agonist

• Pipeline therapies
  • Scenesse (Afamelanotide; Clinuvel Pharmaceuticals)

Future treatment trends in vitiligo

• Key insights summary

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe